Price$0.25+0.00 (+0.08%)
05:00 PM07:00 PM
News · 26 weeks42+50%
2026-02-012026-07-26
Mix2290d
- SEC Filings11(50%)
- Insider5(23%)
- Other4(18%)
- Leadership1(5%)
- Offering1(5%)
Latest news
25 items- SECAEON Biopharma Inc. filed SEC Form 8-K: Other Events8-K - AEON Biopharma, Inc. (0001837607) (Filer)
- SECSEC Form SCHEDULE 13G filed by AEON Biopharma Inc.SCHEDULE 13G - AEON Biopharma, Inc. (0001837607) (Subject)
- SECAEON Biopharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits8-K - AEON Biopharma, Inc. (0001837607) (Filer)
- SECSEC Form 424B4 filed by AEON Biopharma Inc.424B4 - AEON Biopharma, Inc. (0001837607) (Filer)
- PRAEON Biopharma Announces Pricing of Upsized $13.75 Million Public Offering with Accompanying Milestone Warrants Providing Potential for Additional Future FundingIRVINE, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, today announced the pricing of its underwritten public offering to raise up to approximately $43.3 million in gross proceeds based on the approximately $13.75 million in expected gross proceeds from the offering and up to an additional $29.6 million in potential gross proceeds upon the cash exercise in full of the milestone warrants issued in the offering. The offering consists of 42,688,606 shares of common stock of the Company
- SECSEC Form EFFECT filed by AEON Biopharma Inc.EFFECT - AEON Biopharma, Inc. (0001837607) (Filer)
- SECSEC Form S-1MEF filed by AEON Biopharma Inc.S-1MEF - AEON Biopharma, Inc. (0001837607) (Filer)
- SECAmendment: SEC Form S-1/A filed by AEON Biopharma Inc.S-1/A - AEON Biopharma, Inc. (0001837607) (Filer)
- SECSEC Form S-1 filed by AEON Biopharma Inc.S-1 - AEON Biopharma, Inc. (0001837607) (Filer)
- INSIDERDirector Thunen Shelley B was granted 222,684 shares, increasing direct ownership by 618% to 258,705 units (SEC Form 4)4 - AEON Biopharma, Inc. (0001837607) (Issuer)
- INSIDERDirector Palmisano Robert J was granted 222,684 shares, increasing direct ownership by 618% to 258,705 units (SEC Form 4)4 - AEON Biopharma, Inc. (0001837607) (Issuer)
- INSIDERDirector Forth Marc was granted 222,684 shares, increasing direct ownership by 30% to 973,231 units (SEC Form 4)4 - AEON Biopharma, Inc. (0001837607) (Issuer)
- INSIDERDirector Fischer Jost was granted 222,684 shares, increasing direct ownership by 83% to 489,469 units (SEC Form 4)4 - AEON Biopharma, Inc. (0001837607) (Issuer)
- INSIDERDirector Carter Eric G was granted 222,684 shares, increasing direct ownership by 618% to 258,705 units (SEC Form 4)4 - AEON Biopharma, Inc. (0001837607) (Issuer)
- SECAEON Biopharma Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - AEON Biopharma, Inc. (0001837607) (Filer)
- PRAEON Biopharma to Present Data Demonstrating Structural and Functional Comparability of ABP-450 to BOTOX® at the 68th Annual Scientific Meeting of the American Headache SocietyIRVINE, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, today announced the presentation of new analytical and functional data supporting biosimilarity of ABP-450 to BOTOX® at the 68th Annual Scientific Meeting of the American Headache Society ("AHS"), being held June 4-7, 2026 in Orlando, Florida. The poster is being presented by Chad K. Oh, M.D., AEON's Chief Medical Officer. The data being presented today builds on previously reported primary structure findings by adding function
- SECAEON Biopharma Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - AEON Biopharma, Inc. (0001837607) (Filer)
- SECSEC Form 10-Q filed by AEON Biopharma Inc.10-Q - AEON Biopharma, Inc. (0001837607) (Filer)
- SECAEON Biopharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - AEON Biopharma, Inc. (0001837607) (Filer)
- PRAEON Biopharma Reports First Quarter 2026 Financial Results and Provides Corporate Update- Reported positive FDA Type 2a meeting supporting ABP-450's comparative analytical strategy under the 351(k) regulatory pathway - - Strengthened balance sheet through financing transactions and Daewoong note exchange, reducing outstanding debt by more than 90% - - Bolstered leadership team with appointment of John Bencich as Chief Financial Officer - IRVINE, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, reported today its financial results for the first quarter ended March 3
- SECSEC Form DEFA14A filed by AEON Biopharma Inc.DEFA14A - AEON Biopharma, Inc. (0001837607) (Filer)
- SECSEC Form DEF 14A filed by AEON Biopharma Inc.DEF 14A - AEON Biopharma, Inc. (0001837607) (Filer)
- PRAEON Biopharma Sets Annual Shareholder Meeting- Annual Shareholder Meeting to be held at 10:00 am PT on June 17, 2026 - IRVINE, Calif., April 24, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX® (onabotulinumtoxinA) to achieve full-label U.S. market entry, today announced that its Annual Shareholder Meeting will be held at 10:00 am Pacific Time (PT) on Wednesday, June 17, 2026 and will be held in the Company's offices at 5 Park Plaza, Suite 1750, Irvine, CA 92614. Meeting materials are expected to be made available to shareholders on or about April 29, 2026. NYSE Required Disclosure Regarding Audit Opinion
- INSIDERSEC Form 4 filed by Bencich John4 - AEON Biopharma, Inc. (0001837607) (Issuer)
- INSIDERSEC Form 3 filed by new insider Bencich John3 - AEON Biopharma, Inc. (0001837607) (Issuer)
AEON FAQ
5 questionsWhere does AEON stock trade?
AEON Biopharma Inc. (AEON) is listed on AMEX.What sector and industry is AEON in?
AEON Biopharma Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about AEON?
AEON Biopharma Inc. has had 1 recent analyst action on file. The most recent action was from H.C. Wainwright: Buy with a $1800.00 price target on 2023-08-18. Recent price targets cluster around $1800.00.What companies are similar to AEON?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare AEON side-by-side with any of them on Quantisnow.How can I track AEON on Quantisnow?
Quantisnow aggregates AEON Biopharma Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AEON to receive live email and push alerts on every new disclosure.